Published: Monday, February 3, 2025 · 12:31 PM | Updated: Monday, February 3, 2025 · 12:31 PM
📊 286 views
🗝️ Key Points
- Twist Bioscience Corp (TWST, Financial) released its 8-K filing on February 3, 2025, reporting a record revenue of $88.7 million for the first quarter of fiscal 2025,.
- This represents a 24% increase from $71.5 million in the same period of fiscal 2024.
- The company, a leader in synthetic biology, utilizes a proprietary DNA synthesis platform to produce high-quality synthetic DNA efficiently and cost-effectively.
Twist Bioscience Corp (TWST, Financial) released its 8-K filing on February 3, 2025, reporting a record revenue of $88.7 million for the first quarter of fiscal 2025, surpassing analyst estimates of $86.97 million. This represents a 24% increase from $71.5 million in the same period of fiscal 2024. The company, a leader in synthetic biology, utilizes a proprietary DNA synthesis platform to produce high-quality synthetic DNA efficiently and cost-effectively. Twist Bioscience derives a majority of its revenue from the United States.
Performance and Challenges
Twist Bioscience Corp (TWST, Financial) demonstrated robust performance with its eighth consecutive quarter of sequential revenue growth. The company achieved a gross margin of 48.3% in Q1 FY2025, an improvement from 40.5% in Q1 FY2024. Despite these achievements, the company faces challenges, including a net loss of $31.6 million, or $0.53 per share, which, although an improvement from a loss of $43.0 million, or $0.75 per share, in the previous year, still indicates ongoing financial hurdles.
Financial Achievements and Industry Importance
The significant revenue growth and improved gross margins are crucial for Twist Bioscience Corp (TWST, Financial) as it continues to establish itself in the Medical Diagnostics & Research industry. The company’s ability to enhance its gross margin by 7.8 percentage points reflects its operational efficiency and strategic focus on cost management, which are vital for sustaining growth and achieving profitability.
Key Financial Metrics
Twist Bioscience Corp (TWST, Financial) reported a reduction in research and development expenses to $21.3 million from $23.1 million, while selling, general, and administrative expenses increased to $56.2 million from $52.8 million. The company’s adjusted EBITDA improved to $(16.3) million from $(27.8) million, indicating progress towards financial stability.
| Metric | Q1 FY2025 | Q1 FY2024 |
|---|---|---|
| Revenue | $88.7 million | $71.5 million |
| Gross Margin | 48.3% | 40.5% |
| Net Loss | $(31.6) million | $(43.0) million |
| Adjusted EBITDA | $(16.3) million | $(27.8) million |
Analysis and Outlook
Twist Bioscience Corp (TWST, Financial) continues to show promising growth with its innovative DNA synthesis platform. The company’s focus on expanding its customer base, as evidenced by shipping products to approximately 2,376 customers in Q1 FY2025 compared to 2,140 in Q1 FY2024, is a positive indicator of market demand. The company’s Guidance for fiscal 2025 projects total revenue between $372 million and $379 million, with a gross margin expected to exceed 50% by the fourth quarter, highlighting its strategic growth trajectory.
We ended the first quarter of fiscal 2025 with our eighth consecutive quarter of revenue growth and continued improvement in gross margin. We’re starting the fiscal year strong, demonstrating our unwavering commitment to progressing toward adjusted EBITDA breakeven,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
Overall, Twist Bioscience Corp (TWST, Financial) is positioned well for future growth, with its strategic initiatives and financial improvements paving the way for potential profitability and sustained market presence in the synthetic biology sector.
Explore the complete 8-K earnings release (here) from Twist Bioscience Corp for further details.
MORE IN INSIDE INVESTMENT NEWS
We’re raising our Costco price target after a good but not great quarter. Here’s why
Published: Friday, March 6, 2026 · 12:27 AM
Broadcom stock rallies as CEO Tan makes strong case for why AI growth will last
Published: Thursday, March 5, 2026 · 4:04 PM
